Claim your 20% discount on Global Market Reports with code ONLINE20. Limited time only.

What Is The Projected Valuation Of The Nasal Spray Influenza Vaccine Market In The Coming Years?

In the past few years, the market size for nasal spray influenza vaccine has experienced significant expansion. The market is predicted to increase from $1.31 billion in 2024 to $1.48 billion in 2025, growing at a compound annual growth rate (CAGR) of 12.2%. Factors such as improved vaccine accessibility, heightened awareness around flu prevention, increasing importance given to pediatric vaccination, increasing rates of vaccination, and an increased preference for vaccines not requiring a needle, all contributed to the growth observed in the historic period.

Expectations are high for the nasal spray influenza vaccine market size, as it is predicted to expand rapidly in the coming years. By 2029, it is projected to reach $2.38 billion, with an annual compounded growth rate, or CAGR, of 12.7%. This anticipated growth within the forecast period is believed to be largely due to the rising demand for convenient immunization methods, an increase in seasonal influenza cases, expanding government initiatives and support, expected augmentation in the elderly and high-risk demographics, and growing adoption within healthcare frameworks. The forecast period also foresees significant trends such as enhancements in vaccine delivery systems, the integration of mucosal immunity strategies, technological advances in viral vector platforms, progression in cold-chain technology, and the inclusion of mRNA technology.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24326&type=smp

What Drivers Are Accelerating Expansion Of The Nasal Spray Influenza Vaccine Market?

The escalating incidence of flu is anticipated to boost the expansion of the nasal spray flu vaccine in the future. Flu is an intensely infectious viral disease mainly impacting the respiratory system with symptoms such as fever, cough, sore throat, body discomfort, and exhaustion. The rising incidence of flu is chiefly attributed to frequent genetic variations of the flu virus, which allows it to bypass current immunity and spread swiftly across communities. The nasal spray flu vaccine aids in defence against the flu by delivering a mild form of the virus straight into the nasal cavities, prompting an immune response at the common point of viral entry. For instance, the UK Health Security Agency, a government body based in the UK, reported that between the 40th week of 2022 and the 15th week of 2023, a total of 1,681 verified flu-related critical care admissions were reported by 108 NHS trusts in England. This figure is significantly higher than the previous season, which saw only 182 admissions from 114 trusts, rising to 316 admissions by the 39th week of 2022. As a result, the escalating incidence of flu is catalysing the expansion of the nasal spray flu vaccine market.

How Is The Global Nasal Spray Influenza Vaccine Market Broken Down By Segment?

The nasal spray influenza vaccinemarket covered in this report is segmented –

1) By Type: Live Attenuated Influenza Vaccine (LAIV); Inactivated Influenza Vaccine

2) By Administration Method: Single-Dose Administration; Multi-Dose Administration

3) By Age Group: Pediatric; Adult; Geriatric

4) By Distribution Channel: Hospitals; Clinics; Pharmacies; Online Stores; Other Distribution Channels

5) By End User: Healthcare Providers; Individuals; Government Health Departments; Pharmaceutical Companies

Subsegments:

1) By Live Attenuated Influenza Vaccine (LAIV): Trivalent Live Attenuated Influenza Vaccine (Trivalent LAIV); Quadrivalent Live Attenuated Influenza Vaccine (Quadrivalent LAIV)

2) By Inactivated Influenza Vaccine: Whole Virus Inactivated Vaccine; Split Virus Inactivated Vaccine; Subunit Inactivated Vaccine; Adjuvanted Inactivated Vaccine; High-Dose Inactivated Vaccine

Which Market Trends Are Expected To Define The Future Of The Nasal Spray Influenza Vaccine Market?

Leading firms in the nasal spray influenza vaccine market are concentrating on the advancement of novel formulations like live attenuated influenza vaccine in order to boost immune response and enhance patient adherence. Live attenuated influenza vaccine (LAIV) is a flu vaccine composed of live, weakened flu viruses, which aids in preventing flu by stimulating the immune system to create antibodies. It provides protection without causing the illness and offers a more holistic immune response, boosting both local and systemic immunity, thus fortifying the body’s defense against future flu infections. For example, in September 2024, AstraZeneca Plc, a pharmaceutical company based in the UK, gained approval from the American Food and Drug Administration (FDA) for the use of FluMist, a live attenuated influenza vaccine (LAIV) for self-administration by adults up to the age of 49 years or for administration by caregivers to children between 2 to 17 years of age. This marked it as the first and only flu vaccine approved for self- or caregiver-administration in the U.S. The approval was based on comprehensive studies confirming the ability of subjects to accurately self-administer the vaccine, with all participants delivering a complete dose as directed.

Which Firms Are Making The Biggest Impact In The Nasal Spray Influenza Vaccine Market?

Major companies operating in the nasal spray influenza vaccine market are Sanofi Pasteur SA, AstraZeneca PLC, GSK plc, Moderna Inc., CSL Limited, Sinovac Biotech Ltd., Emergent BioSolutions Inc., Serum Institute of India Pvt. Ltd., Beijing Wantai Biological Pharmacy Enterprise Co. Ltd., NPO Microgen JSC, Changchun BCHT Biotechnology Co. Ltd., Mitsubishi Tanabe Pharma Corporation, FluGen Inc., BioDiem Ltd, Starpharma Holdings Limited, Codagenix Inc., Nobilon International B.V., KM Biologics Co. Ltd., Altimmune Inc., Mylab Discovery Solutions Private Limited

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/nasal-spray-influenza-vaccine-global-market-report

Which Geographic Regions Are Creating Strong Demand In The Nasal Spray Influenza Vaccine Market?

North America was the largest region in the nasal spray influenza vaccine market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the nasal spray influenza vaccine market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=24326&type=smp

Browse Through More Reports Similar to the Global Nasal Spray Influenza Vaccine Market 2025, By The Business Research Company

Drug Delivery Devices Market 2025

https://www.thebusinessresearchcompany.com/report/drug-delivery-devices-market

High Flow Nasal Cannula Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/high-flow-nasal-cannula-global-market-report

Inhalation And Nasal Spray Generic Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/inhalation-and-nasal-spray-generic-drugs-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model